不可切除转移性黑色素瘤不同治疗策略的缓解与生存
本研究基于荷兰黑色素瘤治疗登记处数据,分析2012年至2025年7月接受一线系统治疗的不可切除转移性黑色素瘤患者,比较抗PD1、T-VEC、BRAF(/MEK)i等方案的缓解与生存。结果显示各方案客观缓解率相近,T-VEC中位PFS较短但中位OS较优,校正混杂因素后T-VEC与抗PD1的OS差异消失,MSS无差异。
要点
- 抗PD1、T-VEC和BRAF(/MEK)i的ORR分别为53.1%、52.2%和62.7%。
- T-VEC中位PFS为5.6个月,短于抗PD1的8.1个月和BRAF(/MEK)i的9.2个月。
- 校正混杂因素后T-VEC与抗PD1的OS差异消失,MSS无差异。
核心结论
- 对于不可切除的转移性黑色素瘤,一线抗PD1、T-VEC和BRAF(/MEK)i均可诱导具有临床意义且持久的缓解。
- 最佳治疗选择取决于患者和疾病特征以及偏好。
研究设计与样本
- 基于荷兰黑色素瘤治疗登记处的真实世界数据,纳入2012年至2025年7月接受系统治疗的不可切除ITM患者(伴或不伴LNM,III-IVM1a期),共530例。
- 一线治疗分布:抗PD1 213例,T-VEC 182例,BRAF(/MEK)i 67例,IPI 37例,IPI+NIVO 31例。
- 采用多变量Cox模型校正年龄、性别、ECOG PS、LDH和LNM。
主要发现
- ORR:抗PD1 53.1%,T-VEC 52.2%,BRAF(/MEK)i 62.7%。
- 中位PFS:T-VEC 5.6个月(95%CI 4.2-8.1),抗PD1 8.1个月(95%CI 5.9-13.8),BRAF(/MEK)i 9.2个月(95%CI 6.9-14.3)。
- 中位OS:T-VEC未达到(95%CI 61.5-NR),抗PD1 37.2个月(95%CI 32.3-64.7),BRAF(/MEK)i 24.7个月(95%CI 18.0-62.1)。
- 校正混杂因素后,T-VEC与抗PD1的OS差异消失,MSS无差异。
- 在仅有ITM亚组中,T-VEC观察到的OS长于抗PD1和BRAF(/MEK)i;在ITM伴LNM患者中,抗PD1的PFS长于T-VEC但OS相似。
临床怎么用
- 临床决策需结合患者和疾病特征(如分期、LNM、LDH等)及患者偏好选择一线治疗方案。
- 对于仅有ITM的患者,T-VEC可能带来更长的OS;对于ITM伴LNM患者,抗PD1可能提供更长的PFS。
局限性
- T-VEC组基线特征更有利(IV期比例更低、LNM更少、LDH更低),可能影响非校正比较结果。
- 为真实世界回顾性登记研究,存在混杂因素和选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Currently, no comprehensive overview exists of response and survival outcomes for first-line immune checkpoint inhibition, BRAF/BRAF + MEK inhibition (BRAF(/MEK)i), and talimogene laherparepvec (T-VEC) in melanoma patients with unresectable in-transit metastases (ITM). This study aims to provide a real-world overview of these outcomes. METHODS: Using data from the nationwide Dutch Melanoma Treatment Registry, all patients receiving systemic treatment from 2012 to July 2025 for unresectable ITM, with or without lymph node metastases (LNM) (stage III-IVM1a), were analysed for overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and melanoma-specific survival (MSS). A multivariable Cox model adjusted for age, sex, ECOG PS, LDH, and LNM. RESULTS: In total, 530 patients were identified: 213 received first-line anti-PD1, 182 T-VEC, 67 BRAF(/MEK)i, 37 ipilimumab (IPI), and 31 ipilimumab + nivolumab (IPI+NIVO). Patients receiving T-VEC had more favorable baseline characteristics, including less often stage IV disease, less often LNM, and lower LDH. ORR were comparable between treatments: anti-PD1 53.1%, T-VEC 52.2%, BRAF(/MEK)i 62.7%. Median PFS was significantly shorter for T-VEC (5.6months; 95%CI 4.2-8.1) than for anti-PD1 (8.1months; 95%CI 5.9-13.8) and BRAF(/MEK)i (9.2months; 95%CI 6.9-14.3). Median OS favored T-VEC (not reached (NR); 95%CI 61.5-NR) over anti-PD1 (37.2months; 95%CI 32.3-64.7) and BRAF(/MEK)i (24.7months; 95%CI 18.0-62.1), but this difference between T-VEC and anti-PD1 disappeared after adjusting for confounders and no differences were observed in MSS. In the ITM-only subgroup, T-VEC-treated patients demonstrated longer observed OS than anti-PD1 and BRAF(/MEK)i, while in patients with ITM and LNM, anti-PD1 showed longer PFS but similar OS compared with T-VEC. CONCLUSIONS: For ITM unresectable melanoma, first-line anti-PD1, T-VEC, and BRAF(/MEK)i can induce clinically meaningful and durable responses. The optimal treatment choice depends on patient and disease characteristics and preferences.
引用
- Boreel C, de Ruijter J, van Not O, et al. Response and survival in unresectable in-transit metastatic melanoma according to treatment strategy. Eur J Cancer. 2026. PMID: 42335571. doi:10.1016/j.ejca.2026.116889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。